Evidence Hub

Mycobacterium fortuitum infection of the hip joint: a case report and literature review

Zhang W, Zhang C, Shan K, Liu S, Hao J, Song M, Zheng C, Zhao Y et al.

Frontiers in immunology, 2026

Abstract

Osteoarticular infections caused by Mycobacterium fortuitum are exceedingly rare and often result in delayed diagnosis due to nonspecific clinical manifestations. We report a case of septic arthritis of the hip in a 47-year-old man, in which M. fortuitum was identified from synovial fluid by 16S rRNA gene sequencing (99% identity to GenBank reference sequence CP011269.1). Upon definitive diagnosis, antimicrobial therapy was adjusted to intravenous azithromycin and levofloxacin combined with oral trimethoprim-sulfamethoxazole (TMP-SMX). Following clinical improvement, treatment was transitioned to oral azithromycin, levofloxacin, and TMP-SMX for 12 months. At the 18-month follow-up, the patient remained in complete remission without recurrence. This case highlights the critical role of 16S rRNA sequencing in diagnosing non-tuberculous mycobacterial infections and informs therapeutic strategies for similar rare infections.

How strong is the evidence?

Evidence Hub reads this as a case report, done in people. Its evidence level is 5 of 5 (Very low · case / narrative / animal / in vitro / in silico). Case reports, narrative reviews, and animal, cell or computer-model studies give the weakest evidence for human health.

How the five levels of evidence work. The level is assigned automatically from the abstract and can be wrong, so check the paper.

Read the paper

Related studies

Go deeper in Evidence Hub

Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.

Open this study Sign up free